NEW YORK (GenomeWeb News) – A federal court has upheld a jury verdict which awarded Enzo Biochem $48.6 million after finding that Life Technologies has infringed Enzo's patents.

In addition to upholding the damage award, Judge Janet Bond Arterton of US District Court for the District of Connecticut denied Life Tech's request that Enzo's infringement claims are barred by laches and /or equitable estoppel, Enzo said today. The court also denied a motion by Life Tech for a new trial and Enzo's request for reconsideration seeking additional damages.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.

Sponsored by
Thermo Fisher Scientific

In this webinar, the first in the “New Frontiers in Liquid Biopsy Research” series, Bea Bellosillo, head of pathology at the Hospital del Mar, will discuss her experience evaluating an early-access lung cancer panel that detects copy number variants and fusions.